INTRODUCTION
In a paper published in 1992, the present authors noted that in the past 3 decades research workers have pro duced remarkable advances in the pharmacologiC treat ment of major and minor psychopathologic disorders.
These advances have had a major impact on our the ories of the etiology of the mental disorders. However, our understanding of the neurobiologic and psycho logic bases of these disorders has been confIned mainly to the hypothesis-generating stage. We have not been able to establish defInitively the nature of the neurobio logic basis of any known psychiatric disorder. Further more, although the discovery of the phenothiazines, lithium, and the tricyclic drugs in the 1950's launched an era of intensive research on therapeutic mechanisms of action, we are still not clear how any of these drugs act to bring about resolution of these disorders. There fore, the question was raised in their earlier paper, ''Have we been looking in the wrong places or in the wrong way?". No answer was suggested, only the ob servation and questions were raised.
Since that time, we have arranged a panel at a na tional meeting (ACNP 1992) to discuss this issue and have had a number of further discussions with col leagues. In this paper, we offer some thoughts as to where the fIeld may have stumbled.
First, the problem may be that the neurobiology un derlying psychopathologic states is too complex to be devined by our present research tools, even though some of them are very sophisticated: such as, MRI, PET, CAT scans, magnetoencephalography, echo planar im aging, GC-mass spectroscopy, and a variety of molec ular biologic approaches. If this is the case, we will have to await the development of even more sophisticated methodologies. However, other possibilities for the causes of this problem have emerged from our discus sions, and in contrast to the complexity issue, they lend themselves to change now using presently available methodologies. This suggestion and arguments in sup port of it are given in the remainder of this paper.
Borrowing from successes in other medical dis ciplines, in the fIeld's biologic studies of mental dis orders we have treated psychopathologic states as ho mogeneous diagnostic entities, such as depression and schizophrenia. This approach, since the introduction of more refIned and reliable methods for diagnosis (namely, the Research Diagnostic Criteria [Spitzer et al. 1978] ) has worked quite well in certain ways, such as evaluating the efficacy of a variety of drugs, delineat ing the typical time of onset of an illness, describing the natural history of an illness, and specifying gender distributions and demographics. However, in our opin ion, the use of this model to elucidate the neurobiologic bases of these illnesses or the mechanisms of action of psychotropic drugs has led the fIeld astray. In fact, psy-0893-133X/94/$7.00 chopathologic states are not homogeneous entities but are composed of a variety of emotional, behavioral, and cognitive elements (herein referred to as components) that interact to create the disorder or are simply grafted onto the "core" of the disorder.
We suggest that each of these components may have its own neurobiologic basis (as might the core base of the disorder) and that when the illness is treated as a thing, the neurobiology that is related to the compo nents may be confused with those related to the core.
Similarly, hypotheses about the neurobiologic basis of the core disorder, such as the catecholamine hypothe sis of the affective disorders, may actually be more rele vant to a component of the depressive states: one of severe depression's major components is a very high level of anxiety. Some of the earlier identifIed anti depressant drugs have since been found to be potent anxiolytics as well (Kahn et al. 1985; Klein et al. 1978 ).
Although they have demonstrated antidepressant pro perties, it may be that the well-known pharmacologic action of the drugs on brain amine systems is more related to their anxiolytic properties than to their effects on the disorder itself (Katz et al. 1987) ; that is, the an tidepressant action of the drugs is due to some presently unknown biologiC effect. If this very likely scenario is correct, then efforts to relate brain nor adrenergic mech anisms in depression, per se, have a "built in" failure element.
Thus, much of what we have learned about depres sion over the past 4 decades, due to the introduction of these new drugs, is not being applied in our research.
We continue, despite major advances in psychophar macology, to adhere to a unitary model of disease.
Although this model in which psychopathologic
state is a homogeneous entity has obvious advantages for clinical practice and for epidemiologic and pheno menologic research, it is not an effective device for in vestigating the multiple mechanisms of action of drugs.
It is a global approach and, thus, has the effect of ob scuring the process of behavioral change and ultimately limits our capacity to relate these drug-induced changes to etiology.
We suggest that the unitary model can actually work against further understanding of the underlying disorder and how the drug is working and that the al drug's actions on each of the major components be mea sured and that biochemical theories be examined as relating to the other components of the illness or to the interaction of these elements, not necessarily the core.
Van Praag has presented a similar view (van Praag et al. 1975) .
Additional examples might help to make our point.
Direct clinical support for the linkage between schizo phrenia and the brain dopamine system function is ei ther negative or controversial (Bowers 1974; Rimon et al. 1971; Berger et al. 1980 ). However, we recently ex amined the relationship of cerebrospinal fluid (CSF) homovanillic acid (HV A) to a complex component of schizophrenia (psychosis) and found a strong correla tion between the two (n = 24, r = 0.70, P = .00(1) (Maas et al. unpublished observation) . Several other groups have also found this strong correlation and have reported signiftcant correlations between plasma HV A and severity of psychosis (Davis et al. 1991; Maas et al. 1988; Pickar et al. 1986 ).
Another illustrative example is that CSF 5-hydroxy indoleacetic acid (5-HlAA), a metabolite of serotonin (5-HT), was found to be low in a subgroup of depressed patients (Asberg et al. 1976a) . A later report concluded that a low CSF 5-HlAA seemed to be associated with a proclivity of patients to commit suicide (Asberg et aI. 1976b) . This was thought generally to be congruent with a "5-HT theory of depression" and nonspeciftcally that a subtype of depression was associated with a dysfunc tion of brain 5-HT systems. Subsequent research with animals and humans however, has quite conclusively shown that brain 5-HT systems regulate impulsivity and the expression of aggression (Linnoila et al. 1983; Soubrie 1986 ). Regardless of the experimental para digm, this association between the 5-HT system and impulsive aggression has been replicated by most in vestigators. Clearly this has been a successful chapter in the history of psychobiology and biologic psychiatry, but consistent with the theme of this paper, impulsive aggression is not a diagnostic entity but rather a compo nent of behavior and/or emotion that can be associated with pathologic or nonpathologic states.
From a multihospital study of depression, Bowden et al. (1985) reported that the biologic effects of tricyclic drugs on neurotransmitter systems were not specifIc to their therapeutic actions; namely, there were simi lar changes in treatment responders and nome sponders. In contrast, in severe depression, there were correlations of CSF concentrations of neurotransmit ter metabolites with speciftc behavioral components when reexamined in the same hospitalized sample (Redmond et al. 1985) . Cerebrospinal fluid 3-methoxy-5-hydroxyphenylglycole was found to be signiftcantly related to an "arousal" dimension of anxiety and its ex pressive facets, agitation, somatization, and sleep dis order but not a depressed mood-retardation dimension.
This fInding supported the hypothesis that the norepi nephrine (NE) system is associated with the arousal and psychomotor aspects of the disorder, rather than with the core depression factor or with the disorder as a whole.
The major points in this paper can be illustrated in somewhat more detail by comparing certain results from an earlier study of the psychobiology of depres sion (Maas et al. 1980; Katz et al. 1979 ) with fIndings generated by other investigators who reasoned in this componential manner. In the earlier study, the struc ture of the disorder was reexamined in severely de pressed hospitalized patients through the use of a range of behavioral, aff ective, and psychological performance measures. The investigation then focused on studying the nature and sequence of behavioral and emotional changes in patients who clearly responded to treatment with tricyclic drugs. This was done in a similar fashion to how the sequence of drug-induced neurochemical changes would be studied.
The work was based on earlier notions that tricy clic drugs have multiple behavioral effects on the clini cal state (Kielholz, 1968) and that the drug actions on the 5-HT system result in different behavioral changes than actions on the NE system (Carlsson 1976 ).
ON THE STRUCTURE OF DEPRESSION
Examination in the previous study (Maas et al. 1980; Katz et al. 1979 ) of the average componential prohle for a severely depressed sample of 104 patients indicated that the level of anxiety in those patients was almost as high as the level of depressed mood and that hostil ity was signiftcantly higher than in healthy controls (Katz et al. 1984) .
A principal components analysis* of the factor structure of the disorder identifted three independent dimensions: two representing opposite states (in terms of arousal) coexisted in most severely depressed pa tients in this sample. They are a depressed, motorically retarded dimension, and an anxious, agitated, somatically aroused dimension. (The third dimension was hostil it y-interpersonal sensitivity). In this type of empirical analysis of sources of variance, these two dimensions
• The 11 "components" of the disorder are behavioral, affect, cogni tive, and somatic constructs, such as, anxiety, motor retardation, and somatization. They were derived through factor analyses of behavioral rating, self-report, and psychological performance measures on a large sample of depressed patients. The constructs are correlated in vari ous degrees with each other. The "dimensions" are uncorrelated or independent measures; they were derived through a principal com ponents analysis (Morrison 1967) of the intercorrelations of the con structs. Each dimension is measured by combining two or more of the constructs with which it is most highly associated. 
THE SEQUENCE AND NATURE OF TRICYCLIC DRUG ACTIONS IN DEPRESSION
To exemplify how the componential approach was used to study the basis of drug action, the process of be havioral change in those patients who responded to the tricyclic drugs will be briefly described (Katz et al. 1987 . To identify treatment responders stringent out come criteria (not simply "marked" improvement) were tt � \1'" P <0·05 P < 0·02 P < 0·0\ P < O·OOI. P < 0·001 P < 0.001 plasma included: reductions in hostility, anxiety, and distressed (physical) expression. These were followed closely at 2 1/2 weeks by an increase in social adapta tion and reductions in depressed mood and motor retardation .
It was concluded from these behavioral changes that amitriptyline in responsive patients is associated with reducing hostility and anxiety, thus "calming" the organism (accounting in part for its efficacy in the anxi ety disorders), and then with having a secondary "stim ulant" action, resulting in a reduction in motor retarda tion (a similar pattern of action has since been described from this study for imipramine; our unpublished data). 1994-VOL. 10, NO.2 cious for phobias and generalized anxiety disorders (Klein et al. 1978; Kahn et al. 1979) here, we learned that even when the study of tricy clic drug actions was confined to the depressive states, the effects on anxiety and hostility in treat ment responders appeared earlier than those re ported for depressive mood . (Winokur 1980; Dimascio et al., 1979; . These fmdings represented important in formation for basic investigators, who were led to believe that neurochemical effects that occurred later were more important than those that occurred earlier in the treatment process. if they attempt to examine the relationships of these processes to the components of mental disorders prior to turning to the diagnostic model.
5.
The guiding principle is not to rely on general clin ical practice and on a still "developing" diagnostic system to overly influence the design of clinical and basic research in psychopharmacology. We must try to introduce what we have learned over the past few decades regarding the psychobiologic structure and components of these disorders into our ways of describing the syndrome and measuring how its components of behavior and emotion change. Only then will we be able to take full advantage of the remarkable conceptual and technical developments in neuropsychopharmacology.
In summary, we are suggesting that we have con fused the multiple actions of psychotropic drugs on components of the main illness (anxiety and motor be havior in depression; psychosis in schizophrenia) with presumed effects on the "core" disturbance and, as such, have falsely hypothesized that certain central neu rotransmitter systems are associated with the core of the illness rather than with its components only. We suggest that we still do not have any fum and viable data that allows us to understand the main biologic de fect(s) in any major psychopathologic state.
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